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MaCardiovascular disease is one of the leading causes of mortality and morbidity worldwide. Atherosclerosis imaging has
traditionally focused on detection of obstructive luminal stenoses or measurements of plaque burden. However, with
advances in imaging technology it has now become possible to noninvasively interrogate plaque composition and disease
activity, thereby differentiating stable from unstable patterns of disease and potentially improving risk stratiﬁcation. This
manuscript reviews multimodality imaging in this ﬁeld, focusing on carotid and coronary atherosclerosis and how these
novel techniques have the potential to complement current imaging assessments and improve clinical decision making.
(J Am Coll Cardiol Img 2019;-:-–-) © 2019 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).C ardiovascular disease remains the leadingcause of death globally, placing a majorburden on health care services worldwide
(1). Atherosclerosis is the main pathophysiological
process responsible for ischemic heart disease and ce-
rebrovascular disease. It is a systemic, multifocal pro-
cess that starts early in life with a long quiescent
phase before the manifestation of overt disease
(2) and symptoms that vary depending on the
morphology and characteristics of the underlying
plaque. Obstructive atherosclerotic disease in the cor-
onary arteries leads to the development of myocardial
ischemia and angina and is usually characterized by
stable plaque. Alternatively, unstable atheroscleroticN 1936-878X
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vessel occlusion and acute stroke or myocardial
infarction (MI).
Modern imaging techniques now allow for the
direct and noninvasive imaging of atherosclerotic
plaque in the carotid and coronary arteries, for the
ﬁrst time facilitating the assessment of plaque
composition and disease activity (Central Illustration).
In this review we discuss how these novel approaches
might differentiate stable from unstable patterns of
atherosclerosis, and complement existing imaging
techniques. Ultimately these advances hold potential
in improving the care of patients with carotid andhttps://doi.org/10.1016/j.jcmg.2019.03.033
rsity of Edinburgh, Edinburgh, United Kingdom; and
e at Mount Sinai, New York, New York. Dr. Fayad is
nstitute P01 HL131478, R01 HL071021, R01 HL128056,
alth/National Institute of Biomedical Imaging and
0780005). Dr. Dweck is supported by the Sir Jules
oundation (FS/14/78/31020). All other authors have
er to disclose.
2019, accepted March 24, 2019.
ABBR EV I A T I ON S
AND ACRONYMS
CAC = coronary artery
calciﬁcation
CI = conﬁdence interval
CT = computed tomography
CTA = coronary computed
tomography angiography
18F-FDG = 18F-
ﬂuorodeoxyglucose
18F-NaF = 18F-sodium ﬂuoride
HR = hazard ratio
IVUS = intravascular
ultrasound
MI = myocardial infarction
MR = magnetic resonance
PET = positron emission
tomography
USPIO = ultrasmall
superparamagnetic particles of
iron oxide
VH = virtual histology
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2coronary atherosclerosis, although it should
be acknowledged that there are few ran-
domized data, beyond the recent SCOT-
HEART (Scottish Computed Tomography of
the Heart) trial, demonstrating an improve-
ment in outcome with use of even well-
established imaging approaches, resulting in
weak guideline recommendations (3).
CURRENT IMAGING STRATEGIES
The clinical approach to atherosclerosis im-
aging has for many decades been based
around the detection of obstructive luminal
stenoses and the clinical sequelae that can
ensue. In the carotid arteries the degree of
luminal stenosis, assessed by ultrasound,
coronary computed tomography angiography
(CTA), or magnetic resonance (MR) angiog-
raphy, is routinely used to inform decisions
regarding surgical revascularization (4).
However, a signiﬁcant number of strokes
occur in patients with nonobstructive carotidplaque. Indeed, the presence of a severe stenosis
provides only modest risk prediction of future events,
particularly in asymptomatic individuals (5). In the
coronary arteries, CTA can directly assess luminal
stenosis severity aided by the functional assessment
provided by computed tomography (CT) fractional
ﬂow reserve, whereas myocardial stress perfusion
imaging and stress echocardiography detect the
myocardial consequences of obstructive plaques.
However, although stable angina and symptoms of
cardiac ischemia are associated with severe coronary
artery stenoses, most MIs occur at sites of non-
obstructive plaque on antecedent angiography (6).
These ﬁndings, coupled with the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) and BARI-2D (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug
Evaluation) trials (7,8) in which percutaneous coro-
nary intervention failed to reduce the risk of MI
despite effective relief of ischemia, suggest that the
relationship between obstructive stenoses, myocar-
dial ischemia, and adverse outcomes may not be
causal. Consequently, there has been signiﬁcant in-
terest in alternative imaging strategies targeting
different aspects of the atherosclerotic disease
process.
One such strategy has been to quantify the total
atherosclerotic plaque burden, the rationale being that
themore plaques a patient has, themore likely it is that
a plaque rupture will occur and cause a clinical event.
Indeed, regardless of the speciﬁc modality used, allimaging measures of atherosclerotic plaque burden
seem to provide powerful prognostic information
(9,10). In the carotid arteries, ultrasound-derived pla-
que burden assessments improve risk prediction
beyond that provided by cardiovascular risk scores
(11,12). In the coronary arteries, CT calcium scoring
quantiﬁes macroscopic deposits of calciﬁcation and
provides a surrogate of total coronary atherosclerotic
burden. This technique offers powerful prognostica-
tion of incremental value to cardiovascular risk scores.
The relationship between calcium score and major
adverse cardiovascular events including all-cause
mortality, cardiovascular events, and non-fatal MI
has been established in several studies (13,14). A large
observational study involving 25,253 patients in the
United States with a mean follow-up of 6.8 years
showed that survival varied signiﬁcantly by the extent
of coronary artery calciﬁcation (CAC) (p< 0.0001) with
survival rates of 99.4%, 94.7%, and 87.8%, respec-
tively, for CAC scores of 0, 400 to 699, and $1,000
(p < 0.0001) (13). There have been multiple studies
examining the very low event rates in patients with
CAC of zero (15,16). In their meta-analysis of 13 studies
assessing the relationship of CAC with adverse car-
diovascular outcomes in 71,595 asymptomatic pa-
tients, Sarwar et al. (15) demonstrated that 0.47%
without CAC had a cardiovascular event during follow-
up, as compared with 4.14% with CAC. There is also
increasing interest in using incidental CAC observed
on chest CTs performed for noncardiac indications to
improve patient risk prediction and to guide preven-
tative therapy (16).
However, although CAC scoring provides a surro-
gate of the atherosclerotic plaque burden at relatively
low radiation doses (w1 mSv) it actually quantiﬁes
calciﬁed plaques that are themselves relatively un-
likely to cause clinical events. It has therefore been
suggested that atherosclerosis imaging and risk pre-
diction may be improved by considering not only
plaque burden, but also plaque type. Broadly, imag-
ing assessments of plaque type can be categorized
into anatomic assessments of plaque composition and
molecular information about disease activity, both of
which seek to differentiate stable from unstable
atherosclerosis.
STABLE VERSUS UNSTABLE
ATHEROSCLEROTIC PLAQUE
To understand how best to image plaque composition
and disease activity it is ﬁrst important to highlight
some important pathophysiological aspects of
atherosclerotic disease. Atherosclerosis is an inﬂam-
matory process that affects the arterial intima with
CENTRAL ILLUSTRATION Multimodality Assessment of Atherosclerotic Plaque Characteristics and
Disease Activity
Daghem, M. et al. J Am Coll Cardiol Img. 2019;-(-):-–-.
Multimodality noninvasive imaging allows comprehensive analysis of atherosclerotic plaque in the coronary and vascular bed. Beyond the standard assessment of
luminal stenosis and disease burden, emerging techniques enable clinical assessment of plaque characteristics and disease activity. Computed tomography (A) and
magnetic resonance (B to D) provide the registered anatomic background information relating to plaque morphology, which can be combined with positron emission
tomography data 18F-sodium ﬂuoride (E, G), 68Ga-DOTATATE (F), and 18F-ﬂuorodeoxyglucose (H), which has potential to examine multiple markers of plaque
biology. F reproduced from Tarkin et al. (53).
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3extensive lipid deposition, foam cell formation, and
vascular smooth muscle cells migration (17). The
resulting plaque can cause progressive luminal ste-
nosis, ischemia, and symptoms of stable angina (sta-
ble disease) or alternatively rupture abruptly,
resulting in thrombus formation, vessel occlusion,
and myocardial or cerebral infarction (unstable dis-
ease). Indeed, plaque rupture is the main method by
which atherosclerosis causes clinical events, ac-
counting for 60% to 70% of acute MIs (18) and
approximately 90% of ischemic strokes (19).
Unstable plaques that are at high risk of rupture,
so-called “vulnerable plaques,” have certain patho-
logical characteristics that are distinct from those
seen in stable lesions (Figure 1). Although stable le-
sions are associated with a thick ﬁbrous cap, macro-
calciﬁcation and extensive ﬁbrous tissue, vulnerable
plaques are characterized by a large necrotic core,
thin ﬁbrous cap (<65 mm), inﬂammation (predomi-
nantly in the form of macrophage inﬁltration),angiogenesis, plaque hemorrhage, and micro-
calciﬁcation (20). Interestingly, although culprit le-
sions are often associated with a large area of plaque
they frequently have a luminal stenosis of less than
75% because of positive remodeling (20). These
adverse plaque characteristics are frequently found
together within the well-described thin cap ﬁbroa-
theroma (21), and each represents a potential imaging
target.
RATIONALE FOR IMAGING STABLE VERSUS
UNSTABLE PLAQUE
Initial attempts to identify vulnerable, unstable pla-
ques were based around invasive imaging strategies,
predominantly intravascular ultrasound (IVUS) (22),
optical coherence tomography (23), and more recently
near-infrared spectroscopy (24). These approaches
provide excellent spatial resolution and detailed as-
sessments of plaque morphology that are yet to be
FIGURE 1 Pathological Features Associated With Culprit Atherosclerotic Plaque
Thin fibrous cap Positive remodeling
Neoangiogenesis
Intraplaque
haemorrhage
Macrophages
Lumen
Lipid core
Microcalcification
Typical adverse plaque characteristics include macrophage accumulation, a large lipid core, positive remodeling, a thin ﬁbrous cap, and
microcalciﬁcation. Intraplaque microvessels result from angiogenesis driven by hypoxia and inﬂammatory stimuli within the necrotic core.
These vessels can result in intraplaque hemorrhage, which increases the risk of plaque destabilization. Each of these represents a potential
noninvasive imaging target.
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4exceeded by noninvasive techniques. The ability of
virtual histology IVUS (VH-IVUS) to detect adverse
plaques and then to predict outcomes was investi-
gated in the landmark PROSPECT (A Prospective
Natural-History Study of Coronary Atherosclerosis)
study (25). Stone et al. (25) prospectively enrolled 697
patients with acute coronary syndromes undergoing
percutaneous revascularization and performed 3-
vessel VH-IVUS, identifying 596 high-risk plaques
(VH-IVUS-deﬁned thin cap ﬁbroatheromas). Howev-
er, after 3 years’ follow-up only 21 MIs were observed,
indicating that most vulnerable plaques either heal or
rupture subclinically without causing hard clinical
events. What then is the point of identifying vulner-
able plaques? The rationale makes more sense at the
level of the patient by applying noninvasive tech-
niques to image the entire coronary or carotid
vasculature (26). Although individual plaques are
themselves relatively unlikely to cause an event, pa-
tients who develop unstable patterns of disease seem
at higher risk of adverse outcomes (27). One potential
explanation is that patients with a propensity to
develop adverse plaque characteristics develop a
greater number of such lesions at multiple sites and
in different vascular beds over time. Although most
heal, the risk of 1 of these many unstable plaquesrupturing and causing a clinical event is increased,
even if it is unlikely to be the lesion ﬁrst identiﬁed on
imaging.
THE CAROTID ARTERIES
Cerebrovascular disease is 1 of the main causes of
death and the most important cause of disability
globally, placing a signiﬁcant economic burden on
health care services worldwide (28). The underlying
pathology and risk factors are similar to those of cor-
onary artery disease, even though a signiﬁcant pro-
portion of events are attributable to other causes, such
as cardioembolic disease and small-vessel ischemia.
However, because of their location, large size, and
stationary nature, imaging of the carotid arteries is
considerably less challenging than imaging the coro-
nary vasculature. As a consequence most novel plaque
imaging techniques are ﬁrst applied to the carotid ar-
teries, with the added advantage that histological
validation is also feasible if imaging is performed
before carotid endarterectomy. To date, ultrasound,
CT, MR, and positron emission tomography (PET)
have all been used to investigate carotid plaque
composition and disease activity, with MR and PET
techniques holding the greatest promise (Figure 2).
FIGURE 2 Multiparametric Assessments of the Carotid Arteries in a Patient Post– Transient Ischemic Attack
B C
A
(A) Magnetic resonance angiogram of a patient with transient ischemic attack with time of ﬂight image demonstrating a complex culprit lesion in the right internal
carotid artery (green arrow). (B) T1-weighted magnetic resonance images of the same patient with a high T1 signal (red arrow) associated with methemoglobin within
areas of fresh thrombus. (C) Positron emission tomography/magnetic resonance imaging with 18F-sodium ﬂuoride showing increased signal intensity (blue arrow) in the
right internal carotid artery corresponding with stenosis and symptoms.
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5PLAQUE COMPOSITION. Although ultrasound is
widely used to assess carotid luminal stenosis clini-
cally it has a limited ability to assess plaque compo-
sition. Ultrasound can make some distinctions
between different plaque types with echolucent het-
erogeneous plaques representative of more unstable
disease (29) and echogenic plaques reﬂective of
calciﬁc stable lesions (30), but this distinction is yet to
ﬁnd a clinical role. CTA of the carotid arteries pro-
vides high-resolution anatomic imaging that may be
useful in determining stenosis severity where ultra-
sound is difﬁcult to perform (31). Many of the adverse
plaque characteristics that can be identiﬁed in the
coronaries (discussed next) can also be assessed in
the carotids. However, this approach requires radia-
tion and iodinated contrast and is less sensitive and
speciﬁc than MR angiography, which is therefore
usually preferred (32).
MR is well suited to atherosclerotic plaque char-
acterization given the soft tissue contrast it provides.
Carotid plaque imaging can be performed with fast
high-resolution MR black-blood techniques thatprovide good blood suppression and high spatial
resolution, providing detailed visualization of the
adjacent vessel and plaque composition (33). In
addition to measurement of carotid plaque thickness,
volume, and area (34), multispectral MR imaging can
categorize carotid plaque into different tissue types,
quantify lipid content, and identify the presence of a
ruptured ﬁbrous cap (35). Imaging after administra-
tion of gadolinium contrast can further improve the
ability of MR to discriminate lipid core from the
overlying ﬁbrotic cap (36). T1-weighted techniques
hold particular promise in the identiﬁcation of intra-
luminal thrombosis and intraplaque hemorrhage (37).
Methemoglobin, a break down product of hemoglo-
bin, causes T1 shortening, resulting in signal ampli-
ﬁcation on T1-weighted images in areas of unstable
plaque containing recent thrombus or hemorrhage
(38). Finally, MR has the ability to target atheroscle-
rotic plaque inﬂammation, using ultrasmall super-
paramagnetic particles of iron oxide (USPIO). When
USPIO particles are administered intravenously, they
are taken up by macrophages via surface scavenger
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6receptors. The powerful T2* effects of USPIOs subse-
quently result in signal hypointensity in areas with
active macrophage inﬁltration. Using this approach,
increased USPIO uptake has been demonstrated in
culprit carotid plaques post-stroke and asymptomatic
carotid stenoses when compared with nonculprit or
healthy control vessels (39,40). Larger clinical trials
are required to establish a clear role for USPIOs
beyond the research setting.
Increasing data suggest that the presence of
adverse carotid plaque features on MR identiﬁes pa-
tients at increased risk of future cardiovascular
events (41–43). Takaya et al. (41) showed that in
asymptomatic patients with 50% to 70% stenoses,
arteries with thinned or ruptured ﬁbrous caps, intra-
plaque hemorrhage, and a large lipid core on MR were
associated with subsequent cerebrovascular events, a
ﬁnding that was conﬁrmed in a systematic review of 9
studies (44). Studies have also demonstrated an as-
sociation between adverse plaque characteristics in
the carotids and clinical events arising from the cor-
onary arteries (42,43), highlighting the systemic na-
ture of atherosclerosis, and the potential for unstable
plaque detection in one territory to inform about
disease status in other vascular beds.
DISEASE ACTIVITY. Advances in hybrid scanners
now allow combined noninvasive assessment of dis-
ease activity using hybrid PET imaging alongside the
anatomic information provided by CT or MR. Tar-
geted PET radiotracers are injected intravenously and
accumulate in areas where the disease process of in-
terest is active. The photons ejected following colli-
sion of the emitted positron with a free electron can
be detected and localized by the PET scanner. This
information is then fused with the anatomic datasets.
In principle this approach can be used to investigate
the activity of any pathological process, subject to the
availability of a relevant radiotracer. In practice the
availability of tracers approved for human use has
previously been limited, although this is rapidly
changing with the advent of multiple novel tracers
speciﬁcally targeting pathological processes relevant
to cardiovascular disease.
18F-ﬂuorodeoxyglucose (18F-FDG) is a commonly
used tracer that labels cells with high glycolytic
metabolic requirements. These include activated in-
ﬂammatory cells that express high levels of glucose
transporters and rapidly accumulate 18F-FDG.
Increased 18F-FDG uptake in carotid plaque demon-
strates a close association with plaque macrophage
inﬁltration leading to its use as a surrogate of vascular
inﬂammation (45,46). Using 18F-ﬂuoromisonidazole
PET imaging to quantify hypoxia in atheroscleroticplaques, Joshi et al. (47) showed that symptomatic
carotid plaques were more hypoxic than asymptom-
atic lesions and that hypoxia contributes to increased
FDG uptake. Chowdhury et al. (46) showed that
culprit carotid plaque following a cerebrovascular
event demonstrated increased 18F-FDG activity
compared with the contralateral carotid artery. More
recent studies have indicated that 18F-FDG uptake in
the carotids correlates with predicted cardiovascular
risk, although it sometimes fails to discriminate
culprit and nonculprit lesions (48,49). Although pro-
spective outcome data regarding carotid 18F-FDG
uptake are lacking, a recent retrospective study
of 309 patients who underwent 18F-FDG PET-CT,
mostly because of the clinical suspicion of cancer,
demonstrated that uptake in the ascending aorta was
a predictor of future coronary heart disease events
independent of Framingham risk scores, and was
associated (50). 18F-FDG uptake has also been used to
monitor vascular wall inﬂammation in response to
antiatherogenic therapies. In a recent meta-analysis
of 7 studies with a combined total of 287 partici-
pants, statin treatment was associated with a signiﬁ-
cant reduction in arterial wall inﬂammation, based on
tissue-to-background ratio (TBR) measurement by
18F-FDG PET-CT imaging (51). Multicenter prospective
studies are now required to conﬁrm the clinical role of
18F-FDG in assessment of atherosclerotic plaque
inﬂammation, discriminating stable from unstable
plaques, predicting cardiovascular prognosis, and
monitoring response to therapies.
Although 18F-FDG is convenient and cheap, it is a
glucose analogue an(53)d therefore not speciﬁc for
inﬂammation. There has therefore been growing in-
terest in the use of more inﬂammation-speciﬁc
tracers, such as DOTATATE and 18-kDa translocator
protein (TSPO) tracers. DOTATATE targets the so-
matostatin receptor subtype-2 (SSTR2), which is
abundant on the surface of proinﬂammatory M1
macrophages. Pedersen et al. (52) demonstrated
increased in vivo uptake of 64Cu-DOTATATE in ca-
rotid plaque, with correlation of this activity with
macrophage burden on histology. Tarkin et al. (53)
demonstrated increased 68Ga-DOTATATE PET uptake
in culprit carotid plaque, with this tracer seeming to
outperform 18F-FDG.
The 18-kDa translocator protein (TSPO), formally
known as the peripheral benzodiazepine receptor, is
found within the outer membrane of mitochondria
and is highly expressed within macrophages
and microglia in the brain (54). Several PET
tracers targeting this protein have been explored
as inﬂammation-speciﬁc tracers, including the
prototypical 11C-PK11195, which has demonstrated
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7increased uptake in culprit carotid plaques following
stroke, independent of vessel stenosis, and correlated
with inﬂammatory cell burden on histology (55). In
patients with carotid disease, 11C-PK11195 uptake can
distinguish between recently symptomatic and
asymptomatic plaque and improves risk stratiﬁcation
(55). However, this tracer is limited by high nonspe-
ciﬁc binding and a short half-life (20 min) that
necessitates onsite cyclotron facilities (56). Second-
generation TSPO tracers have also been disap-
pointing, primarily because of their variable binding
in patients with different forms of the rs6971
genetic polymorphism (57). Third-generation TSPO
radiotracers are under evaluation that seem to be less
sensitive to TSPO binding afﬁnity and the rs6971
polymorphism.
Finally, tracers investigating other pathological
processes are also being explored. 18F- sodium ﬂuo-
ride (18F-NaF) is a cheap and widely available PET
tracer that preferentially binds to areas of newly
developing microcalciﬁcation (58). 18F-NaF therefore
targets the unstable early phase of the calciﬁcation
process and provides information about calciﬁcation
activity that is different and complementary to the
stable macrocalciﬁc plaques identiﬁed on CT. 18F-NaF
PET has been used to study vascular calciﬁcation ac-
tivity in a range of conditions including aortic ste-
nosis (59), abdominal aortic aneurysm disease (60),
and both carotid and coronary atherosclerosis (61).
18F-NaF uptake in the carotid arteries has been vali-
dated against histology, with increased uptake
observed in plaques with multiple different adverse
characteristics, and 18F-NaF offering improved
discrimination of culprit plaque post-stroke
compared with 18F-FDG (48). Larger studies investi-
gating the role of 18F-NaF in the assessment of carotid
atherosclerosis are currently underway.
THE CORONARY ARTERIES
Ischemic heart disease is the most common global
cause of death (28). There is consequently a major
focus on primary and secondary prevention, with an
attendant need to accurately identify patients who
might beneﬁt from preventative therapies. As in the
carotids, there is interest in using advanced imaging
to differentiate stable coronary atheroma from the
unstable patterns of disease associated with plaque
rupture and clinical events. However, these ap-
proaches are considerably more challenging in the
small-caliber, highly mobile coronary arteries (62).
Over recent years advances in contrast CTA technol-
ogy have overcome many of these hurdles. Indeed,
contrast CT is being used increasingly in the clinicalassessment of patients with suspected coronary ar-
tery disease, supported by data from 2 large
randomized controlled trials: PROMISE (Outcomes of
Anatomical versus Functional Testing for Coronary
Artery Disease) (63) and SCOT-HEART (64). In SCOT-
HEART the use of CTA increased diagnostic cer-
tainty, changed clinical management, and reduced
fatal or nonfatal MI at 5 years compared with standard
care (2.3% vs. 3.9%; hazard ratio [HR]: 0.59; 95%
conﬁdence interval [CI]: 0.41 to 0.84) (65). PROMISE
recruited a lower risk population with a shorter
duration of follow-up. After 25 months, there was no
difference in the composite primary outcome (death,
MI, hospitalization for unstable angina, or major
procedural complication), although at 12 months the
risk of death or nonfatal MI was lower in the CTA
group compared with the control arm (mandated
stress imaging) (HR: 0.66; 95% CI: 0.44 to 1.00) (63).
When these trials were considered as part of a meta-
analysis again CT was associated with a reduction in
MI, although there was no difference in mortality
(66). It is important to note that in both trials roughly
one-half of the observed MIs occurred in patients
with nonobstructive disease on their baseline scan
(63). Indeed, the value of CT imaging probably lies in
its ability to identify obstructive and nonobstructive
plaque and to provide an overall assessment of pla-
que burden. On the back of this growing clinical
adoption the next step is to assess whether CT or
hybrid assessments of plaque type can further reﬁne
patient assessment (67,68).
PLAQUE COMPOSITION. Most simply, CT can be
used to categories plaques as noncalciﬁed, partially
calciﬁed, and calciﬁed based on their attenuation
values (Hounsﬁeld units) (69). One study of patients
with suspected coronary artery disease demonstrated
that at the patient level, higher rates of 3-year major
adverse cardiovascular events were observed in pa-
tients with noncalciﬁed versus calciﬁed plaque 22.7%
versus 5.5% (70). Data from the ICONIC (Incident
COroNary Syndromes Identiﬁed by Computed To-
mography) register found that culprit lesions had a
92% higher volume of noncalciﬁc plaque than control
subjects (71). However, CT can also offer more
detailed information and identiﬁcation of speciﬁc
adverse plaque characteristics (Figure 3). These
include positive remodeling, spotty calciﬁcation (a
marker of early macrocalciﬁcation rather than true
microcalciﬁcation), the napkin ring sign (a signature
CT lesion appearance of low-attenuation surround by
a rim of high-attenuation), and low attenuation pla-
que (<30 HU) as a marker of a large necrotic core.
These adverse plaque features have been well
FIGURE 3 Assessment of Coronary Plaque Characteristics on Coronary Computed Tomography Angiography
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(A) Low-attenuation plaque (red arrow) in the proximal left anterior descending artery with spotty calciﬁcation and associated vessel stenosis. (B)
Nonobstructive plaque in proximal left anterior descending artery with spotty calciﬁcation (green arrow). (C) An atherosclerotic plaque with positive
remodeling (blue arrow) and low-attenuation plaque in the left anterior descending artery. (D) Williams et al. (68) demonstrated that patients with
obstructive disease and 1 or more high-risk plaque had a 10-fold increased risk of subsequent myocardial infarctions than patients with normal coronaries.
Figure 3D reproduced from Williams et al. (68).
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8validated against intravascular imaging, are more
frequently observed in patients with MI compared
with patients with stable angina (72,73), and are
associated with an increased incidence of future car-
diovascular events (74,75). Motoyama et al. (76)
investigated 3,158 patients who underwent CTA for
suspected or known coronary artery disease. They
identiﬁed adverse plaque features of positive
remodeling or low attenuation (<30 HU) in 294 pa-
tients, 16% of whom went on to have acute coronary
syndrome compared with only 1.4% of patients
without adverse plaques (Figure 3). Similarly, a recent
prospective study of 245 patients with nonobstructive
coronary artery disease on CTA reported that when
adjusted for clinical variables the presence of at least
2 adverse plaque features was associated with a sta-
tistically higher rate of cardiac death and/or acute
coronary syndrome (HR: 7.54; 95% CI: 2.43 to 23.34;
p ¼ 0.0005) (77).
Secondary analyses exploring the associations be-
tween adverse plaque characteristics and outcomeshave been performed in both the PROMISE and SCOT-
HEART cohorts. The PROMISE data showed that even
after adjusting for risk factors and stenosis severity,
the presence of adverse plaque features is associated
with an increased risk of major adverse cardiac
events (HR: 1.72; 95% CI: 1.89 to 3.93), with stronger
associations observed in younger patients, those with
nonobstructive disease, and women (67). This is
consistent with the SCOT-HEART data that demon-
strated a 3-fold increase in events in patients with
adverse plaque (positive remodeling or low-
attenuation plaque) (68). The presence of both
obstructive disease and adverse plaque had a syner-
gistic effect with a resultant 10-fold increase in these
patients compared with those with normal coronary
arteries (68). Importantly, however, the predictive
effect of adverse plaque features and obstructive
disease was not signiﬁcant when adjusted for calcium
score, which emerged as the only independent pre-
dictor of fatal or nonfatal MI. Although these data
support the hypothesis that patients with adverse
FIGURE 4 Assessment of Coronary Plaque Characteristics on Magnetic Resonance
All Coronary Events
Cu
m
ul
at
iv
e 
Ev
en
t-
Fr
ee
 R
at
e
0.8
1.0
0.6
0.4
PMR <1.4 + No CAD PMR <1.4 + CAD
PMR ≥1.4 + No CAD PMR ≥1.4 + CAD
PMR <1.4 + No CAD
PMR <1.4 + CAD
PMR ≥1.4 + No CAD
PMR ≥1.4 + CAD
Number of Patients at Risk
p < 0.001 by the log-rank test
p = 0.021
p = 0.001
0.2
0.0
0 12
340
69
85
74
340
67
81
60
327
50
60
51
145
21
20
24
24 36
Months of Follow-Up
48 60 72
A
B
C
(A) High-intensity plaque in the proximal left anterior descending artery (yellow arrow) on noncontrast T1-weighted magnetic resonance. (B) T1-weighted images
coregistered with magnetic resonance coronary angiogram, increased signal at site of high-intensity plaque (yellow arrow). (C) Kaplan-Meier curves comparing the
probability of coronary events in patients with and without high-intensity plaque on noncontrast T1-weighted imaging. Adverse plaque characteristic conferred a higher
incidence of adverse clinical events. CAD ¼ coronary artery disease; PMR ¼ plaque-to-myocardium signal intensity ratio. Reproduced from Noguchi et al. (86).
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9plaque features and an unstable pattern of disease are
at increased risk of future events, they highlight an
important caveat: that no study of high-risk plaque
identiﬁcation has yet demonstrated incremental
prognostic beneﬁt over and above more simple
markers of overall plaque burden, namely the calcium
score.
A recent and novel CT method for identifying
unstable coronary atherosclerosis is the assessment
of epicardial adipose tissue. This is the visceral fat
surrounding the heart that is thought to interact
with adjacent coronary atherosclerotic plaque in a
bidirectional manner. For many years paracrine ef-
fects of pericardial fat on coronary plaque have been
proposed, modulating underlying atheroma via
activation of local inﬂammatory pathways and
increased neovascularization (78). Recent studies
have shown that higher epicardial fat volumes are
observed in patients with noncalciﬁed compared
with calciﬁed plaques (79) and associated with an
increased rate of future cardiovascular events (80).
However, the improved spatial and temporal reso-
lution of contemporary CTA now allows study of thisinteraction in the other direction. The rationale is
that coronary plaque inﬂammation alters the
composition of the adjacent epicardial fat, an effect
that can be detected by changes in CT attenuation.
This technique was validated by Antonopoulos et al.
(81), and has been shown to identify patients at
increased risk of death in a recent retrospective
multicenter outcome study (82). With further vali-
dation this approach could become a useful tech-
nique to measure inﬂammation retrospectively on
routinely acquired CT scans, although further work
is required to understand where in the coronary
vasculature it is best measured, the effects of coro-
nary stents on attenuation measurements, and
whether this approach predicts MI as well as
death (83).
MR angiography techniques are less developed
than CT and not in widespread clinical use. MR is
able to visualize coronary plaque and detect adverse
features (62), such as positive remodeling (84), but
such approaches have largely been limited to indi-
vidual coronary territories, restricting potential util-
ity. However, T1-weighted approaches looking for
TABLE 1 Positron Em
Tracer
18F-FDG
18F-NaF
Ga68- or Cu64-
DOTATATE
11C-PK11195
USPIO
18F-FDG ¼ 18F-ﬂuorodeoxy
FIGURE 5 Assessment of Disease Activity in the Coronary Arteries
A B
C D
Positron emission tomography/computed tomography imaging of the coronaries with 18F-sodium ﬂuoride. (A) Invasive coronary angiography
showing a culprit lesion in right coronary artery (red arrow). (B) Intense focal 18F-sodium ﬂuoride uptake is observed at the site of the culprit
plaque on positron emission tomography/computed tomography. (C) Invasive coronary angiography showing culprit plaque in the left
circumﬂex artery (red arrow). (D) Intense focal 18F-sodium ﬂuoride uptake is observed at the site of the culprit plaque on positron emission
tomography/computed tomography.
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10plaque hemorrhage and luminal thrombus can be
applied across the entire coronary vasculature, with
recent studies conﬁrming increased signal in culprit
plaques post-MI (85) (Figure 4), and that theission Tomography–Based Molecular Imaging in Carotid and Coronary D
Pathological Process Biological Target
Inﬂammation Glucose analogue Increased uptake seen in
Microcalciﬁcation Hydroxyapatite Increased uptake demon
myocardial uptake, b
Inﬂammation Somatostatin receptor
subtype-2 (SSTR2)
Localizes to culprit coro
In some cases lack o
needed.
Inﬂammation Translocator protein
(TSPO)
Increased uptake in culp
Limited by high nons
Inﬂammation Surface scavenger
receptors
Has been used in magne
plaques and asympto
interpretation.
glucose; 18F-NaF ¼ 18F-sodium ﬂuoride; USPIO ¼ ultrasmall superparamagnetic iron oxide.presence of such high-intensity coronary plaque
identiﬁes patients at increased future risk of car-
diovascular events (86). This approach is deserving
of further study.isease
Research Application and Limitations
carotid disease (46), but myocardial uptake limits its use in coronaries.
strated in both culprit coronary and carotid plaque (61). Limited
ut overspill from bones can affect interpretation.
nary and carotid plaque (53). No physiological uptake in the myocardium.
f availability limits its use even in research. Further validation studies are
rit carotid plaques following stroke, independent of vessel stenosis (55).
peciﬁc binding and short half-life. Further validation studies are needed.
tic resonance imaging, with uptake demonstrated in culprit carotid
matic carotid stenoses (39,40). High blood pool signal may affect signal
HIGHLIGHTS
 Assessment of coronary and carotid
atherosclerotic plaque composition is
possible using computed tomography and
magnetic resonance imaging.
 Disease activity in coronary and carotid
atherosclerotic plaque can be assessed
using molecular imaging techniques, such
as positron emission tomography.
 These imaging assessments of plaque
type can be used to differentiate stable
from unstable patterns of atherosclerosis
and potentially to improve patient risk
stratiﬁcation.
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11DISEASE ACTIVITY. With modern PET-CT scanners,
accurate coregistration, improved blood-pool correc-
tion, and state-of-the-art motion correction have
facilitated the measurement of disease activity in the
coronary arteries (87,88). Unfortunately, 18F-FDG
imaging in the coronary arteries is challenging
because of the high metabolic activity of the
myocardium, which obscures signal in adjacent cor-
onary plaque in a third of patients, even despite di-
etary restrictions (89). This has led to interest in more
speciﬁc tracers, including 68Ga-DOTATATE, which
similar to the carotids localizes to culprit coronary
plaques post-MI (53).
18F-NaF is characterized by very low uptake in the
myocardium (roughly half to two-thirds lower than in
the blood-pool) (90), which makes this tracer well
suited to the detection of signal in the coronary ar-
teries. Increased 18F-NaF uptake is observed in coro-
nary plaques (Figure 5) with multiple adverse features
on CT, VH-IVUS, and optical coherence tomography
(OCT), and in the culprit plaques of patients post-MI
(61). At the patient level increased 18F-NaF activity
is observed in patients with higher Framingham risk
scores (91). To further investigate the clinical utility
of 18F-NaF in the coronary arteries and its role in risk
prediction, the prospective multicenter PREFFIR
(Prediction of Recurrent Events With 18F-Fluoride)
trial is currently underway (ClinicalTrials.gov
NCT02278211).
FUTURE DIRECTIONS
With advances in scanner technology it is now
possible to image atherosclerotic plaque composition
and disease activity and to differentiate stable from
unstable patterns of disease in the carotid and coro-
nary vessels. Although several of these techniques
have now become well established, their incremental
clinical value over and above more standard imaging
approaches has yet to be established. Large-scale
prospective studies are required for this purpose
and in particular need to demonstrate added value to
simpler plaque burden measurements before the
added time and resources in assessing plaque type
can be justiﬁed.
Of the available plaque composition assessments,
CTA seems to offer the greatest potential given the
advanced plaque characterization that it provides and
the growing clinical role that this technique is
assuming. More advanced molecular imaging tech-
niques, such as PET, hold great promise in improving
pathological understanding of atherosclerosis,particularly with the development of novel tracers
targeting macrophages, microcalciﬁcation, angio-
genesis, and thrombus formation (Table 1). With
ongoing technological advances these PET tech-
niques may also ﬁnd a clinical role, further
improving risk stratiﬁcation and potentially guiding
the use of invasive or expensive treatments in pa-
tients with advanced disease. However, any such
beneﬁts need to be substantial to justify the addi-
tional radiation exposure and expense associated
with molecular imaging.
CONCLUSIONS
Rapid advances in noninvasive cardiovascular imag-
ing now allow assessment of plaque composition and
atherosclerotic disease activity in the aorta, carotid,
and coronary arteries and differentiation of stable
versus unstable disease states. Although this has
provided important pathophysiological insights,
further research is now required to investigate
whether such approaches provide any incremental
clinical information beyond standard patient
assessments.
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